Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Recursion Pharmaceuticals Inc
Revenue
Recursion Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
Revenue
$44.6m
|
CAGR 3-Years
124%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Recursion Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Recursion Pharmaceuticals Inc
Breakdown by Segments
Recursion Pharmaceuticals Inc
Total Revenue:
44.6m
USD
|
Operating Revenue:
43.9m
USD
|
Grant Revenue:
699k
USD
|
See Also
What is Recursion Pharmaceuticals Inc's Revenue?
Revenue
44.6m
USD
Based on the financial report for Dec 31, 2023, Recursion Pharmaceuticals Inc's Revenue amounts to 44.6m USD.
What is Recursion Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 3Y
124%
Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for Recursion Pharmaceuticals Inc have been 124% over the past three years .